血府逐瘀方治疗心脑血管疾病的活性成分与机制综述
该综述系统总结了血府逐瘀方(XFZYF)的活性成分、血肠迁移成分、质量控制、药代动力学、药理机制及临床应用。XFZYF含11味药材,已开发8种剂型,其成分分为酚酸类、黄酮类、三萜皂苷类等;临床广泛用于内科与外科。机制可能涉及调节氨基酸代谢、非编码RNA、炎症反应、突触可塑性、趋化因子、氧化应激、脂质代谢、线粒体功能、血小板聚集、血管生成及肠道菌群等。
要点
- XFZYF含11味药材,已开发8种剂型,成分包括酚酸、黄酮、三萜皂苷等。
- 临床用于心脑血管疾病,可能通过抗炎、抗氧化、调节代谢等多途径起效。
- 需建立全面质量控制标准,并加强联合用药的安全性评估。
核心结论
- XFZYF可能通过调节氨基酸代谢、非编码RNA、炎症反应、突触可塑性、趋化因子、氧化应激、脂质代谢、线粒体功能、血小板聚集、血管生成及肠道菌群等发挥心脑血管保护作用。
研究设计与样本
- 综述检索PubMed、Web of Science和CNKI数据库至2024年,关键词包括血府逐瘀、心血管疾病、脑血管疾病、化学成分、迁移成分、质量控制及药理特性。
主要发现
- XFZYF已开发出8种不同剂型用于临床应用。
- XFZYF由11味药材组成,已鉴定或初步表征的化合物分为酚酸类、黄酮类、三萜皂苷类、单萜糖苷类、亚精胺类和苯酞类。
- 临床上XFZYF广泛用于内科和外科疾病。
关键数值与推荐
- XFZYF由11味药材组成,有8种剂型。
- 成分分类包括酚酸类、黄酮类、三萜皂苷类、单萜糖苷类、亚精胺类和苯酞类。
临床怎么用
- 临床可用于心脑血管疾病的内科与外科治疗,但需关注质控标准与联合用药安全性。
- 未来应推进血肠迁移成分的相互作用与配伍研究,并促进AI驱动的标准化与现代化。
局限性
- 需建立XFZYF全面质量控制标准。
- 需加强XFZYF临床安全性评估,尤其是联合用药。
- 需推进迁移成分相互作用与配伍的系统研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGIC RELEVANCE: The rapid increase in cardiovascular and cerebrovascular diseases (CCVDs) is a significant threat to human health. Traditional Chinese medicine (TCM) offers unique therapeutic advantages. Xuefu Zhuyu Formula (XFZYF), a classic TCM prescription, has been widely used in clinical practice to treat CCVDs and other related conditions. AIM OF THE STUDY: The study aimed to comprehensively elucidate the bioactive components and mechanisms of XFZYF and serve as a reference for future research. The current development, structural characteristics, blood- and intestine-migratory components, quality control measures, pharmacokinetics, pharmacological mechanisms, and clinical applications of XFZYF were systematically summarized. MATERIALS AND METHODS: A comprehensive literature search was conducted up to 2024 in PubMed, Web of Science, and the China National Knowledge Infrastructure (CNKI) database using the keywords: "Xuefu Zhuyu", "cardiovascular disease", "cerebrovascular disease", "chemical constituents", "migratory components", "quality control", and "pharmacological properties". RESULTS: Eight distinct dosage forms of XFZYF have been developed for clinical application. XFZYF consists of 11 medicinal ingredients, and various compounds have been identified or preliminarily characterized. These compounds are broadly classified into phenolic acids, flavonoids, triterpenoid saponins, monoterpene glycosides, spermidines, and phthalides. Clinically, XFZYF is widely applied in both internal medicine and surgical settings. CONCLUSION: XFZYF may exert protective effects against the onset and progression of CCVDs by modulating amino acid metabolism, non-coding RNAs, inflammatory responses, synaptic plasticity, chemokines, oxidative stress, lipid metabolism, mitochondrial function, platelet aggregation, angiogenesis, and gut microbiota. Additionally, perspectives on current limitations and directions for future research were discussed. 1) Establishment of a comprehensive quality control standard for XFZYF. 2) Enhancement of the clinical safety assessment of XFZYF, especially in combination therapies. 3) Advancement of the systematic study of the interactions and compatibility of migratory components. 4) Promotion of AI-driven strategies in the standardization and modernization of TCM.
引用
- Dai X, Yang J, Ye Y, et al. Bioactive components and mechanisms of the traditional Chinese herbal formula Xuefu Zhuyu formula in the treatment of cardiovascular and cerebrovascular diseases. J Ethnopharmacol. 2025. PMID: 40280375. doi:10.1016/j.jep.2025.119873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。